Article
BioCryst Collaborates to Battle Bird Flu
Author(s):
BioCryst Pharmaceuticals, Inc. (Birmingham, AL, www.biocryst.com) and Shionogi & Co., Ltd. (Osaka, Japan, www.shionogi.co.jp) have signed an exclusive license agreement to develop and commercialize BioCryst's lead influenza neuraminidase inhibitor, peramivir, in Japan for the treatment of seasonal and potentially life-threatening human influenza.
BioCryst Pharmaceuticals, Inc. (Birmingham, AL, www.biocryst.com) and Shionogi & Co., Ltd. (Osaka, Japan, www.shionogi.co.jp) have signed an exclusive license agreement to develop and commercialize BioCryst’s lead influenza neuraminidase inhibitor, peramivir, in Japan for the treatment of seasonal and potentially life-threatening human influenza. BioCryst retains all rights to commercialize peramivir in North America, Europe, and other countries outside of Japan and Korea.
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
